1. Home
  2. CLWT vs KPRX Comparison

CLWT vs KPRX Comparison

Compare CLWT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CLWT

Euro Tech Holdings Company Limited

HOLD

Current Price

$1.23

Market Cap

9.5M

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

N/A

Current Price

$2.79

Market Cap

10.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLWT
KPRX
Founded
1971
1998
Country
Hong Kong
United States
Employees
N/A
13
Industry
Professional and commerical equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5M
10.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CLWT
KPRX
Price
$1.23
$2.79
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
4.8K
63.2K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$1.76
52 Week High
$1.63
$4.18

Technical Indicators

Market Signals
Indicator
CLWT
KPRX
Relative Strength Index (RSI) 54.23 62.37
Support Level $1.13 $2.57
Resistance Level $1.31 $2.94
Average True Range (ATR) 0.06 0.15
MACD 0.00 0.02
Stochastic Oscillator 45.68 72.18

Price Performance

Historical Comparison
CLWT
KPRX

About CLWT Euro Tech Holdings Company Limited

Euro Tech Holdings Co Ltd is a distributor and manufacturer of technology instruments as well as an environmental engineering services provider. It is engaged in the marketing and trading of water and wastewater related process control, analytical and testing instruments, disinfection equipment, supplies, and related automation systems. There are two operating segments of the company. The Trading and manufacturing segment, which is the key revenue driver, includes distribution of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies and power generation equipment. The Engineering segment includes water and waste-water treatment engineering and air pollution control business. The majority of the revenue is generated from Hong Kong.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: